Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590564 · ClinicalTrials.gov registry record · Phase 2
SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00590564: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00590564 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590564, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Researchers want to see whether Sho-saiko-to (SST) can help in patients with chronic hepatitis C. Chronic hepatitis C may cause swelling within the liver and this can lead to scar tissue. In some patients, severe scarring of the liver, liver failure and liver cancer can occur. Standard treatment for chronic hepatitis C is a drug called interferon with or without another drug called ribavirin. There are a number of side effects that some patients are unable to take. Other patients may have an initial response, but then the virus and the inflammation come back. Sho-saiko-to is an herbal medicine that has been used for many years in Asia to treat liver disease. The purpose of the study is to evaluate whether Sho-saiko-to may improve liver swelling and injury caused by chronic hepatitis C.
Interventions
- DRUG Sho-saiko-to
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2002-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590564
The ClinicalTrials.gov registry entry for NCT00590564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sho-saiko-to is the first listed.
NCT00590564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590564 about?
NCT00590564 is a clinical study titled "SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study". Researchers want to see whether Sho-saiko-to (SST) can help in patients with chronic hepatitis C. Chronic hepatitis C may cause swelling within the liver and this can lead to scar tissue. In some patients, severe scarring of the liver, liver failure and liver cancer can occur. Standard treatment for...
What is the current status of trial NCT00590564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2002-10. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00590564?
The interventions under investigation include: Sho-saiko-to (DRUG).
Who is sponsoring clinical trial NCT00590564?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.